Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced that the first patient has been enrolled in the VITAL-CML trial, w ...
(RTTNews) - Enliven Therapeutics, Inc. (ELVN) shares jumped 50.86%, trading at $23.33, up $7.86, after the company reported positive initial Phase 1b data from its ENABLE clinical trial of ELVN-001 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results